Sort by
Refine Your Search
-
Listed
-
Employer
- University of Oxford
- ;
- KINGS COLLEGE LONDON
- University of London
- Durham University
- UNIVERSITY OF VIENNA
- DURHAM UNIVERSITY
- Heriot Watt University
- King's College London
- University of Birmingham
- University of Liverpool
- ; University of Oxford
- Aston University
- St George's University of London
- University of Cambridge
- University of Lincoln
- 6 more »
- « less
-
Field
-
We are seeking to appoint a Senior Bioinformatician to lead and develop cutting-edge research into genome regulation and identification of novel therapeutic targets for rare disease. You will join
-
statistical shape analysis, Riemannian geometry, time series and stochastic processes, and Bayesian statistics. Key responsibilities: To carry out research within the framework of the project, under
-
targets. You will take a lead on development of computational approaches to integrate multi-omics data from patient samples, including DNA methylation, histone modifications, single-cell transcriptomics and
-
interaction of Mycobacterium tuberculosis with macrophages to explore targets for anti-virulence approaches in tuberculosis drug development. The work will involve establishing and running immunology and
-
use computational approaches to mine natural biodiversity in gene sequences to identify engineering targets to increase lipid content and enhance the water use efficiency. The project will make use
-
target groups respond to science. This is the first large-scale study of its kind, and your results will establish a legacy of scientists working with funding councils to defend their research. Cutting
-
evidencing: which scientific discoveries are more impactful than others; whether public attitudes to science change over time; how the public learn and talk about science; how different target groups respond
-
and PhD students. Research spans a wide range. Current interests include: Bayesian statistics; modelling of structure, geometry, and shape; statistical machine learning; computational statistics; high
-
diseases (CVDs), yet significant uncertainty remains regarding which disease contexts, patient populations, and time points are most amenable to therapeutic targeting. This position will involve
-
molecular therapeutics. Their ability to target challenging biological sites and modulate intracellular functions¿capabilities beyond those of traditional small molecules and biologics¿make them a promising